COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells

Cancer Research

Volumn 71, Issue 7, 2011, Pages 2664-2674

  Fujita, Mitsugu ^a,b   Kohanbash, Gary ^a,c   Fellows Mayle, Wendy ^b   Hamilton, Ronald L ^a,b   Komohara, Yoshihiro ^a,b   Decker, Stacy A ^d   Ohlfest, John R ^d   Okada, Hideho ^a,b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CD11B ANTIGEN; CELECOXIB; CYCLOOXYGENASE 2; CYTOSINE; DIMETHYLCELECOXIB; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GUANINE; MONOCYTE CHEMOTACTIC PROTEIN 1; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN G2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CCL2 GENE; CELL MATURATION; CONTROLLED STUDY; COX2 GENE; CYTOTOXIC T LYMPHOCYTE; DRUG MECHANISM; ENZYME INHIBITION; GENE; GLIOMA; GRANULOCYTE; IMMUNE DEFICIENCY; LYMPHOCYTIC INFILTRATION; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; PROTEIN MOTIF; SUPPRESSOR CELL; TUMOR MICROENVIRONMENT; WILD TYPE;

ALLELES; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CD8-POSITIVE T-LYMPHOCYTES; CHEMOKINE CCL2; CHEMOKINE CXCL10; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DINOPROSTONE; FEMALE; GLIOMA; LYSOSOMAL-ASSOCIATED MEMBRANE PROTEIN 1; MALE; MICE; MICE, INBRED C57BL; MYELOID CELLS; PYRAZOLES; SULFONAMIDES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 79953324535     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-3055     Document Type: Article

References (38)

1. Scheurer ME, El-Zein R, Thompson PA, Aldape KD, Levin VA, Gilbert MR, et al. Long-term anti-inflammatory and antihistamine medication use and adult glioma risk. Cancer Epidemiol Biomarkers Prev 2008;17:1277-81.
2. Sivak-Sears NR, Schwartzbaum JA, Miike R, Moghadassi M, Wrensch M. Case-control study of use of nonsteroidal antiinflammatory drugs and glioblastoma multiforme. Am J Epidemiol 2004;159:1131-9. (Pubitemid 38747260)
3. Rodriguez PC, Hernandez CP, Quiceno D, Dubinett SM, Zabaleta J, Ochoa JB, et al. Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med 2005;202:931-9. (Pubitemid 41396893)
4. Ochoa AC, Zea AH, Hernandez C, Rodriguez PC. Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin Cancer Res 2007;13:721s-6s.
5. Sinha P, Clements VK, Fulton AM, Ostrand-Rosenberg S. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res 2007;67:4507-13. (Pubitemid 46815102)
6. Wang D, Dubois RN. Eicosanoids and cancer. Nat Rev Cancer 2010;10:181-93.
7. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009;9:162-74.
8. Huang B, Lei Z, Zhao J, Gong W, Liu J, Chen Z, et al. CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers. Cancer Lett 2007;252:86-92. (Pubitemid 46734559)
9. Wiesner SM, Decker SA, Larson JD, Ericson K, Forster C, Gallardo JL, et al. De novo induction of genetically engineered brain tumors in mice using plasmid DNA. Cancer Res 2009;69:431-9.
10. Fujita M, Scheurer ME, Decker SA, McDonald HA, Kohanbash G, Kastenhuber ER, et al. Role of type 1 IFNs in antiglioma immunosurveillance - using mouse studies to guide examination of novel prognostic markers in humans. Clin Cancer Res 2010;16:3409-19.
11. Yoshida S, Amano H, Hayashi I, Kitasato H, Kamata M, Inukai M, et al. COX-2/VEGF-dependent facilitation of tumor-associated angiogenesis and tumor growth in vivo. Lab Invest 2003;83:1385-94. (Pubitemid 37267822)
12. Miliaras S, Miliaras D, Vrettou E, Zavitsanakis A, Kiskinis D. The effect of aspirin and high fibre diet on colorectal carcinoma: a comparative experimental study. Tech Coloproctol 2004;1:s59-61.
13. Jimeno A, Amador ML, Kulesza P, Wang X, Rubio-Viqueira B, Zhang X, et al. Assessment of celecoxib pharmacodynamics in pancreatic cancer. Mol Cancer Ther 2006;5:3240-7. (Pubitemid 46092067)
14. Park W, Oh YT, Han JH, Pyo H. Antitumor enhancement of celecoxib, a selective cyclooxygenase-2 inhibitor, in a Lewis lung carcinoma expressing cyclooxygenase-2. J Exp Clin Cancer Res 2008;27:66.
15. U.S. Food and Drug Administration. Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. Food and Drug Administration; 2005.
16. Muthuswamy R, Urban J, Lee JJ, Reinhart TA, Bartlett D, Kalinski P. Ability of mature dendritic cells to interact with regulatory T cells is imprinted during maturation. Cancer Res 2008;68:5972-8.
17. Fujita M, Zhu X, Sasaki K, Ueda R, Low KL, Pollack IF, et al. Inhibition of STAT3 promotes the efficacy of adoptive transfer therapy using type-1 CTLs by modulation of the immunological microenvironment in a murine intracranial glioma. J Immunol 2008;180:2089-98.
18. Fujita M, Zhu X, Ueda R, Sasaki K, Kohanbash G, Kastenhuber ER, et al. Effective immunotherapy against murine gliomas using type 1 polarizing dendritic cells - significant roles of CXCL10. Cancer Res 2009;69:1587-95.
19. Schonthal AH, Chen TC, Hofman FM, Louie SG, Petasis NA. Celecoxib analogs that lack COX-2 inhibitory function: preclinical development of novel anticancer drugs. Expert Opin Investig Drugs 2008;17:197-208. (Pubitemid 351578200)
20. Levy G, Tsuchiya T. Salicylate accumulation kinetics in man. N Engl J Med 1972;287:430-2.
21. Dzenko KA, Song L, Ge S, Kuziel WA, Pachter JS. CCR2 expression by brain microvascular endothelial cells is critical for macrophage transendothelial migration in response to CCL2. Microvasc Res 2005;70:53-64. (Pubitemid 41565409)
22. + CTL epitopes with distinct functional profiles. J Immunol 2005;174:2212-9.
23. Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 2009;182:4499-506.
24. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2010;377:31-41
25. Youn JI, Nagaraj S, Collazo M, Gabrilovich DI. Subsets of myeloidderived suppressor cells in tumor-bearing mice. J Immunol 2008;181:5791-802.
26. Movahedi K, Guilliams M, Van Den Bossche J, Van Den Bergh R, Gysemans C, Beschin A, et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 2008;111:4233-44.
27. Brown CE, Vishwanath RP, Aguilar B, Starr R, Najbauer J, Aboody KS, et al. Tumor-derived chemokine MCP-1/CCL2 is sufficient for mediating tumor tropism of adoptively transferred T cells. J Immunol 2007;179:3332-41.
28. Deshmane SL, Kremlev S, Amini S, Sawaya BE. Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res 2009;29:313-26.
29. Mantovani A, Sica A, Allavena P, Garlanda C, Locati M. Tumor-associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation. Hum Immunol 2009;70:325-30.
30. Greifenberg V, Ribechini E, Rossner S, Lutz MB. Myeloid-derived suppressor cell activation by combined LPS and IFN-gamma treatment impairs DC development. Eur J Immunol 2009;39:2865-76.
31. + effector T cells. J Leukoc Biol 2002;71:669-76.
32. + T regulatory cell activities in lung cancer. Cancer Res 2005;65:5211-20.
33. Jordan JT, Sun W, Hussain SF, DeAngulo G, Prabhu SS, Heimberger AB. Preferential migration of regulatory T cells mediated by gliomasecreted chemokines can be blocked with chemotherapy. Cancer Immunol Immunother 2008;57:123-31. (Pubitemid 350043644)
34. Purow B, Schiff D. Advances in the genetics of glioblastoma: are we reaching critical mass?Nat Rev Neurol 2009;5:419-26.
35. Schwartzbaum J, Ahlbom A, Malmer B, Lönn S, Brookes AJ, Doss H, et al. Polymorphisms associated with asthma are inversely related to glioblastoma multiforme. Cancer Res 2005;65:6459-65. (Pubitemid 40994435)
36. Wrensch M, Wiencke JK, Wiemels J, Miike R, Patoka J, Moghadassi M, et al. Serum IgE, tumor epidermal growth factor receptor expression, and inherited polymorphisms associated with glioma survival. Cancer Res 2006;66:4531-41.
37. Scheurer ME, Amirian E, Cao Y, Gilbert MR, Aldape KD, Kornguth DG, et al. Polymorphisms in the interleukin-4 receptor gene are associated with better survival in patients with glioblastoma. Clin Cancer Res 2008;14:6640-6.
38. Rodero M, Marie Y, Coudert M, Blondet E, Mokhtari K, Rousseau A, et al. Polymorphism in the microglial cell-mobilizing CX3CR1 gene is associated with survival in patients with glioblastoma. J Clin Oncol 2008;26:5957-64.